Islet amyloid in type 2 (non-insulin-dependent) diabetes

被引:26
作者
Clark, A [1 ]
Charge, SBP [1 ]
Badman, MK [1 ]
deKoning, EJP [1 ]
机构
[1] UNIV OXFORD,DEPT HUMAN ANAT,OXFORD OX1 3QX,ENGLAND
关键词
islet amyloid polypeptide; diabetes; islets of Langerhans; transgenic mice; amyloid; toxicity;
D O I
10.1111/j.1699-0463.1996.tb00680.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Amyloid deposits are found in pancreatic islets of 90% of type 2 (non-insulin-dependent) diabetic subjects at postmortem. Islet amyloid is formed from islet amyloid polypeptide (IAPP). IAPP is a 37 amino acid peptide which is a normal constituent of beta cells and is co-secreted with insulin in animals and in man. The causative factors for fibrillogenesis of IAPP are unclear, but could be related to the sequence of IAPP and abnormal production of the peptide. The lack of islet amyloid in rodent models of diabetes is due to proline substitutions in the amyloidogenic region of IAPP. Amyloid fibrils are deposited between beta cells and islet capillaries: fibrils in invaginations of the plasma membrane may interfere with membrane signalling and insulin release. Amyloid fibrils are formed within 2 days in culture in islets isolated from transgenic mice expressing the gene for human IAPP, but not in vivo. Overexpression and decreased clearance of human IAPP from islet spaces may be important factors. Progressive deposition of IAPP fibrils combined with the associated reduction in the insulin-secreting beta cells is likely to contribute to deterioration of islet function in the course of type 2 diabetes.
引用
收藏
页码:12 / 18
页数:7
相关论文
共 50 条
[31]   DETERMINANTS OF MILD FASTING HYPERTRIGLYCERIDEMIA IN NON-INSULIN-DEPENDENT DIABETES [J].
BAYNES, C ;
HENDERSON, AD ;
HUGHES, CL ;
RICHMOND, W ;
JOHNSTON, DG ;
ELKELES, RS .
JOURNAL OF INTERNAL MEDICINE, 1991, 229 (03) :267-273
[32]   EFFECT OF INSULIN-TREATMENT ON SERUM LIPOPROTEIN(A) IN NON-INSULIN-DEPENDENT DIABETES [J].
KUUSI, T ;
YKIJARVINEN, H ;
KAUPPINENMAKELIN, R ;
JAUHIAINEN, M ;
EHNHOLM, C ;
KAUPPILA, M ;
SEPPALA, P ;
VIIKARI, J ;
KUJANSUU, E ;
RAJALA, S ;
LAHTI, J ;
NISKANEN, L ;
MARJANEN, T ;
SALO, S ;
RYYSY, L ;
TULOKAS, T ;
TASKINEN, MR .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1995, 25 (03) :194-200
[33]   NON-INSULIN-DEPENDENT DIABETES-MELLITUS - DEFECTS IN INSULIN-SECRETION [J].
WOLFFENBUTTEL, BHR ;
VANHAEFTEN, TW .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1993, 23 (02) :69-79
[34]   Familial aggregation of type 2 (non-insulin-dependent) diabetes mellitus in South India absence of excess maternal transmission [J].
Viswanathan, M ;
McCarthy, MI ;
Snehalatha, C ;
Hitman, GA ;
Ramachandran, A .
DIABETIC MEDICINE, 1996, 13 (03) :232-237
[35]   Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes [J].
Scrocchi, LA ;
Chen, Y ;
Wang, F ;
Han, K ;
Ha, K ;
Wu, L ;
Fraser, PE .
LETTERS IN PEPTIDE SCIENCE, 2003, 10 (5-6) :545-551
[36]   Islet amyloid polypeptide (IAPP) transgenic rodents as models for type 2 diabetes [J].
Matveyenko, Aleksey V. ;
Butler, Peter C. .
ILAR JOURNAL, 2006, 47 (03) :225-233
[37]   Inhibitors of islet amyloid polypeptide fibrillogenesis, and the treatment of type-2 diabetes [J].
Louise A. Scrocchi ;
Yan Chen ;
Feng Wang ;
Kyung Han ;
Katherine Ha ;
Ling Wu ;
Paul E. Fraser .
Letters in Peptide Science, 2003, 10 :545-551
[38]   Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes [J].
Powell, DS ;
Maksoud, H ;
Chargé, SBP ;
Moffitt, JH ;
Desai, M ;
Fihlo, RLD ;
Hattersley, AT ;
Stratton, IM ;
Matthews, DR ;
Levy, JC ;
Clark, A .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2003, 60 (02) :105-110
[39]   Non-insulin-dependent diabetes mellitus in populations at risk: the Pima Indians [J].
Charles, MA ;
Eschwege, E ;
Bennett, PH .
DIABETES & METABOLISM, 1997, 23 :6-9
[40]   GENETICS OF NON-INSULIN-DEPENDENT DIABETES-MELLITUS - THE END OF A NIGHTMARE [J].
FROGUEL, P ;
VIONNET, N ;
COHEN, D ;
PASSA, P .
PATHOLOGIE BIOLOGIE, 1992, 40 (10) :977-979